Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer

NCT03989362 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: Vopratelimab
DRUG: Ipilimumab

Sponsor

Jounce Therapeutics, Inc.